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Abstract 
Background: Plasmodium vivax infections commonly contain multiple genetically distinct parasite clones. The 
detection of multiple-clone infections depends on several factors, such as the accuracy of the genotyping method, 
and the type and number of the molecular markers analysed. Characterizing the multiplicity of infection has broad 
implications that range from population genetic studies of the parasite to malaria treatment and control. This study 
compared and evaluated the efficiency of neutral and non-neutral markers that are widely used in studies of molecu-
lar epidemiology to detect the multiplicity of P. vivax infection.
Methods: The performance of six markers was evaluated using 11 mixtures of DNA with well-defined proportions 
of two different parasite genotypes for each marker. These mixtures were generated by mixing cloned PCR products 
or patient-derived genomic DNA. In addition, 51 samples of natural infections from the Brazil were genotyped for all 
markers. The PCR-capillary electrophoresis-based method was used to permit direct comparisons among the markers. 
The criteria for differentiating minor peaks from artifacts were also evaluated.
Results: The analysis of DNA mixtures showed that the tandem repeat MN21 and the polymorphic blocks 2 (msp1B2) 
and 10 (msp1B10) of merozoite surface protein-1 allowed for the estimation of the expected ratio of both alleles in the 
majority of preparations. Nevertheless, msp1B2 was not able to detect the majority of multiple-clone infections in 
field samples; it identified only 6 % of these infections. The merozoite surface protein-3 alpha and microsatellites (PvMS6 
and PvMS7) did not accurately estimate the relative clonal proportions in artificial mixtures, but the microsatellites 
performed well in detecting natural multiple-clone infections. Notably, the use of a less stringent criterion to score 
rare alleles significantly increased the sensitivity of the detection of multi-clonal infections.
Conclusions: Depending on the type of marker used, a considerable amplification bias was observed, which may 
have serious implications for the characterization of the complexity of a P. vivax infection. Based on the performance 
of markers in artificial mixtures of DNA and natural infections, a minimum panel of four genetic markers (PvMS6, 
PvMS7, MN21, and msp1B10) was defined, and these markers are highly informative regarding the genetic variability of 
P. vivax populations.
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Background
Plasmodium vivax is globally the most widely distributed 
Plasmodium species that infects humans, being com-
mon in tropical and sub-tropical areas outside of Africa 
[1, 2]. Several factors have highlighted the clinical impor-
tance of malaria caused by P. vivax, such as the spread of 
parasite resistance to available drugs [3]. In addition, the 
concept of vivax malaria as a benign disease has evolved 
with the description of severe cases and even deaths [4–
6]. Finally, dormant forms of the parasite in the liver, i.e., 
hypnozoites, act as a reservoir for the disease and have 
hindered the control of malaria caused by P. vivax [7]. 
These factors have all increased interest in vivax malaria, 
primarily in the new Malaria Eradication Research 
Agenda (malEra) [8].
Plasmodium vivax infections are often characterized by 
the presence of two or more genetically distinct parasites 
in the same individual [9–11]. These infections are very 
common in malaria-endemic areas worldwide [12–15] 
and can arise from a single mosquito bite carrying a mix-
ture of parasites or from inoculation by different mos-
quitoes carrying single clones. Additionally, relapses of 
P. vivax infection due the reactivation of hypnozoites can 
contribute to increased clonal diversity. As a result, the 
association between the multiplicity of P. vivax infection 
and malaria endemicity is weak, with areas of low ende-
micity sometimes featuring high rates of multiple infec-
tions [14–17]. The number of parasite clones in a patient 
varies greatly, and some infections contain up to nine 
clones [12]. Characterizing the multiplicity of infection 
has broad implications ranging from population genetic 
studies of the parasite to malaria treatment and control. 
First, evolutionary and population genetic studies rely on 
accurate parasite genotype/haplotype inference, which 
is non-trivial when more than one clone is present and 
clones differ at examined loci [18, 19]. Second, charac-
terizing the within-host diversity is essential to address 
several issues, such as differentiation between new infec-
tion and recrudescence, in order to better estimate the 
true risk of treatment failure and explore the dynamics of 
clones influenced by host immunity during anti-malarial 
treatment or challenge with vaccine [12, 20, 21]. Third, 
malaria patients infected by multiple parasite strains have 
been shown to be at a higher risk of treatment failure 
[22]. Thus, a broad understanding of the genetic diversity 
of parasite populations can contribute to the definition of 
control measures, including an appropriate anti-malarial 
treatment.
The publication of the complete genome sequence of P. 
vivax has led to the discovery of many molecular mark-
ers, such as microsatellites, tandem repeats and single 
nucleotide polymorphisms (SNPs) [23]. These markers 
have proven useful for population genetic studies and for 
the characterization of the multiplicity of P. vivax infec-
tions. However, many studies have shown that the char-
acterization of multi-clonal infections depends on both 
the accuracy of the genotyping method, and the type and 
number of the molecular markers analysed [24, 25]. Thus, 
the use of different approaches may significantly affect 
the ability to detect multi-clonal P. vivax infections and 
may hinder comparability among studies [26, 27]. Fur-
thermore, the method used may influence the estimation 
of the relative abundance of clones in multiple infections.
This study evaluated and compared the ability of dif-
ferent molecular markers—two microsatellites, one tan-
dem repeat and three antigen-coding genes—to estimate 
the number and the relative abundance of alleles present 
in multi-clonal P. vivax infections. In order to simulate 
multiple-clone infections with well-defined proportions 
of different parasite genotypes, cloned PCR products or 
patient-derived genomic DNA were artificially mixed. In 
addition, the performance of these markers was also eval-
uated by genotyping P. vivax isolates that had infected 
patients from the Brazilian Amazon. The PCR-capillary 
electrophoresis-based method (PCR-CE), which offers 
several advantages, such as high resolution (1 bp), repro-
ducibility in determining fragment size, and a cost-bene-
fit for the analysis of a large number of field samples, was 
used to genotype all markers [28]. Although this method 
of quantification is subject to some limitations, many 
studies have shown that the peak heights correspond to 
the actual relative proportions of clones in an infection 
when data are properly normalized [24, 29, 30]. The abil-
ity to identify less abundant clones depends on the cri-
teria applied to differentiate minor peak from artifacts, 
which allows the multiplicity of infection to be properly 
defined. Two criteria are commonly used to score multi-
ple alleles per locus: cut-off values for minor peak detec-
tion of (1) one-fourth or (2) one-third the height of the 
predominant peak [9, 17, 31–34]. Although the one-third 
criterion is the most widely used, few studies have evalu-
ated the sensitivity of these criteria for the detection of 
multi-clonal infections [24]. Here, the results showed 
the necessity to apply the less stringent one-fourth cri-
terion to increase the detection of multiple-clone infec-
tions. Specifically, a minimum panel of four markers 
was defined to characterize the multiplicity of a P. vivax 
infection.
This is the first study to show that depending on the 
type of marker used for P. vivax analysis, a consider-
able amplification bias is observed. This relationship 
may have serious implications for the characterization 
of the complexity of an infection. Moreover, these find-
ings were facilitated by the use of parasite DNA samples 
with well-defined proportions of each genotype in arti-
ficial mixtures as well as the use of molecular markers 
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with different features, such as neutral and non-neutral 
markers.
Methods
Field isolates and DNA extraction
Fifty-one P. vivax isolates were obtained from the blood 
of infected patients from the Brazilian Amazon, includ-
ing 22 samples previously characterized as having 
multi-clonal infection [9, 15]. The mono-infections were 
confirmed by 6 to 11 molecular markers described here 
or elsewhere [9, 15]. DNA was extracted from whole 
blood samples using the Gentra Puregene Blood Kit (Qia-
gen, Valencia, CA, USA), according to the manufacturer’s 
protocol. Ethical approval for the study was obtained 
from the Ethics and Research Committee of René Rachou 
Research Center (Protocol number 20/2009).
Artificial mixtures of DNA
To simulate multiple-clone infections with a known pro-
portion of each clone, two plasmid DNAs (pDNA), each 
containing distinct variants of each locus (A-type and 
B-type alleles), were mixed in different proportions to 
produce 11 different mixtures prior to PCR amplifica-
tion and genotyping. To set up mixtures, each pDNA 
was quantified in a NanoDrop 2000 spectrophotometer 
(Thermo Scientific, San Jose, CA, USA), and the num-
ber of plasmid copies was estimated as follows: plasmid 
copy number = [(6.02 × 1023 copies/mol) × DNA quan-
tity (g)]/[DNA length (bp) ×  660 (g/mol/bp)]. Two-fold 
serial dilutions of pDNA were prepared for each experi-
ment, with DNA concentrations ranging from 3.13 × 107 
to 1.0 × 109 copies/µL of the plasmid. For all PCR reac-
tions, 1  µL of each plasmid in a specific concentration 
was added to reaction to produce a curve with varied 
proportions of pDNA. In addition, mixed genomic DNA 
(gDNA) samples from two P. vivax-infected patients pre-
viously identified as being mono-clonal were also used to 
simulate multi-clonal infections [9]. To this end, samples 
with similar parasitaemia (microscopy) and leukocyte 
counts (leukogram determination) were selected, and 
the gDNA concentration was determined using a spec-
trophotometer. The parasite density in samples from P. 
vivax-infected patients ranged from 3000 to 7500 para-
sites/µL, as determined by light microscopy. The genomic 
DNA was two-fold serially diluted (8–0.25  ng), and 1 
µL of each sample was added to each PCR reaction. To 
estimate the relative abundance of alleles in the mixture 
after genotyping, the ratio between the two peak heights 
(given in arbitrary fluorescence units) was calculated for 
each mixture. Data shown represent the average of two 
independent experiments, and each experiment was ana-
lysed in duplicate in an automatic DNA sequencer.
The observed data were normalized according to 
Havryliuk et al. [24] to allow direct comparisons between 
expected ratios and observed values. Specifically, the 
peak height ratios observed in a 1:1 mixture were used as 
normalization factors in subsequent analyses.
PCR amplification and genotyping of molecular markers
The six loci selected for this study consisted of two 
microsatellites (PvMS6 and PvMS7), one tandem repeat 
(MN21), and blocks 2 and 10 of merozoite surface pro-
tein-1 (msp1B2 and msp1B10) and merozoite surface 
protein-3 alpha (msp3α). These fragments were ampli-
fied using specific primers and conditions as described 
previously [10, 15, 35]. The nested approach described by 
Koepfli et al. [10] was modified to capture more variabil-
ity and used to amplify block 2 of msp1 and msp3α. The 
primers used in the nested reaction were changed to the 
following: msp1B2 (forward primer 5′GACGATATTGG 
AAAATTGGA3′; reverse primer 5′CTCCTTCAGCA 
CTTTCACGCGCTT3′); and for msp3α (forward primer 
5′CCCGCATGAGGAGCCAAACAACTT3′; reverse 
primer 5′CCTTTGCATTTTTTGCCGCAG3′). For 
msp1b2, these new primers anneal in a more conserved 
region of the gene, and the new msp3α primers were 
designed to amplify a larger and more polymorphic frag-
ment. All forward primers used in the genotyping were 
conjugated to the fluorescent dye 6-FAM. The following 
mixture was subjected to nested PCR: 1 μL of PCR prod-
uct of the first reaction (diluted 1:1000 in H2O), 1 µM of 
each primer (Integrated DNA Technologies, San Diego, 
CA, USA), 0.125 mM of dNTPs, 2 μL of 10X Taq poly-
merase buffer (Invitrogen, Carlsbad, CA, USA) and 1 U 
of recombinant Taq polymerase (Invitrogen) in a final 
volume of 20 μL. The magnesium concentration varied 
from 3  mM (msp1B2) to 2  mM (msp3α). The cycling 
parameters were set to the following: 1 cycle at 94  °C 
for 4 min; 25 cycles consisting of 40 s of denaturation at 
94  °C, 30  s of annealing at 64  °C (for msp1B2) or 63  °C 
(msp3α), and 40 s of elongation at 72 °C; and a final cycle 
of 10 min at 72 °C.
For capillary electrophoresis, 2 μL of the diluted PCR 
products (1:20 in H2O) was mixed with the size stand-
ard ET-Rox 550 or ET-Rox 900 (Amersham Biosciences) 
diluted 1:40 in 0.1 % Tween-20 to a final volume of 10 μL. 
After capillary electrophoresis, alleles were visualized 
and scored in an automatic DNA sequencer (MegaBACE; 
Amersham Biosciences, Piscataway, NJ, USA). Their 
lengths and relative abundance (peak heights in electro-
pherograms) were determined using the MegaBACE™ 
Fragment Profiler version 1.2 software (Amersham Bio-
sciences). For the electropherogram analysis, the mini-
mum peak height was set to 150 arbitrary fluorescence 
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units (rFU). Additionally, cut-off values for minor peak 
detection of one-fourth or one-third the height of the 
predominant peak were used to exclude artifact peaks.
Cloning of PCR products
For each locus, two variants differing in size were cloned 
into the pGEM-T Vector (Promega) or TOPO-TA Clon-
ing Vector (Invitrogen): 305 or 203  bp for PvMS6; 362 
or 350  bp for PvMS7; 641 or 692  bp for msp3α; 402 or 
429 bp for msp1B2; 252 or 258 bp for msp1B10; 292 or 
257  bp for MN21 (Additional file  1). The fragments 
cloned into the pGEM-T Vector were termed A-type, 
and those cloned into the TOPO-TA Cloning Vector 
were termed B-type. The PCR amplicons were cloned 
according to the manufacturer’s protocol. Recombinant 
vectors were used to transform the competent Escheri-
chia coli Top10 strain using thermal shock, and the cells 
were plated in LB agar supplemented with ampicillin 
(50 μg/mL), X-Gal (1 mg/mL) and IPTG (0.1 mM) [36]. 
The plasmid DNAs were extracted using a QIAprep Spin 
Miniprep Kit (Qiagen).
Results
Evaluation of amplification bias in artificial mixtures 
of plasmid DNA
Mixtures of DNA were prepared using known propor-
tions of two different pDNAs (cloning vectors, each 
containing one of the two variants of a locus studied). 
Overall, the efficiencies of six genetic markers (two 
microsatellites, one tandem repeat, and three antigen-
coding markers) to detect alleles in artificial mixtures 
were compared. All six molecular markers accurately 
identified the correct alleles in samples containing a sin-
gle clone. However, an amplification bias was detected 
for most markers in the 1:1 mixtures; specifically, one of 
the two alleles at a given locus was predominantly ampli-
fied (Additional files 2 and 3).
Only three of the six markers (msp1B2, msp1B10 and 
the tandem repeat MN21) were able to detect the cor-
rect proportions of each clone in most of the artificial 
mixtures (Fig.  1 and Additional file  2). For both msp1 
markers, the correspondence between the expected and 
observed proportions was evident, even for non-nor-
malized data (Additional file 2). Thus, six to seven of ten 
tested dilutions corresponded to the expected propor-
tions of the two cloned msp1 markers in the infection 
(Fisher´s exact test, P  >  0.05). These results agree with 
linear regression analyses, which indicated a significant 
relationship between the actual peak height and the 
known mixture of pDNA based on high regression values 
(R2) and a slope close to the expected value of unity for 
both msp1 markers and MN21 (Additional file 2).
In most mixtures, the correct proportions of the 
two clones were not accurately determined using the 
microsatellite markers PvMS6 and PvMS7 (Additional 
file 2). Nevertheless, these markers were sensitive to the 
decreased relative abundance of alleles in artificial mix-
tures, mainly when the A-type allele was predominant 
(for mixtures ranging from 1:0.5 to 1:0.0313) (Fig. 1a). For 
PvMS6, the analysis of the non-normalized data showed 
that the shorter (B-type) allele was preferentially ampli-
fied, even when the expected ratio of A-type to B-type 
alleles was as high as 1:0.125 (Additional file  2). For 
example, the B-type allele clearly predominated (1:1.49) 
for this expected ratio (1:0.125). A similar result was 
observed for mixtures of genomic DNA without cloning 
(Additional file 4).
Criteria for detection of rare alleles in artificial mixtures 
of plasmid DNA
Two criteria are frequently used to score rare alleles in 
multiple-clone infections: (1) the one-third criterion, 
wherein peak heights of rare alleles are equal or higher 
than 33  % of the height of the predominant peak, and 
(2) the one-fourth criterion, in which a cut-off value of 
25 % is applied to detect rare alleles. When the one-third 
criterion was applied, PvMS6 and both msp1 mark-
ers detected 36–45 % of multiple infections (Fig. 2). For 
PvMS6, the use of the one-fourth criterion allowed an 
increase of 18 % in the detection rate of multiple infec-
tions, increasing the overall rate to 54  %. For PvMS7, 
msp3α and MN21, the multi-clonal parasite rates were 
below 30  % using either of the cut-off value criteria (25 
or 33 %).
Based on the tested mixtures, the application of the 
one-third criterion allowed the detection of the rare 
alleles up to a dilution of 1:0.0625 (16× diluted), whereas 
the one-fourth criterion permitted the identification of 
rare alleles in more unbalanced mixtures (32x diluted) 
(Additional file 5). Overall, the use of the one-fourth cri-
terion improved the detection rate of multiple infections 
up to 33 %, as shown for 1:1 mixtures.
Genotyping of Plasmodium vivax isolates from natural 
infections
Fifty one samples from the Brazilian Amazon were gen-
otyped with the six markers based on the one-fourth 
criterion, and 36 (70.6  %) samples were identified as 
multiple-clone infections, for which at least one locus 
contained more than one allele. The greatest number of 
multiple-clone infections was identified using msp1B10 
and the microsatellite markers (27 and 24 % of all sam-
ples, respectively) (Fig.  3a). Conversely, the msp1B2 
marker only identified three (5.9  %) multiple-clone 
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infections. A detailed analysis of the data showed that 
three additional infections were likely lost by the msp1B2 
marker due to a weak fluorescent signal for the rare allele. 
Moreover, half of the 36 multi-clonal infections defined 
using the one-fourth criterion were identified using two 
or more markers (Fig. 3b). msp1B10 identified 38 % of the 
multiple-clone infections, and this proportion increased 
to 68  % when msp1B10 was combined with PvMS6 
(Fig.  3b). The further addition of PvMS7 and MN21 
detected 95  % of the clonal infections. Combined with 
an analysis based on msp3α, the percentage of identified 
multi-clonal infections reached 100 %.
The potential of each marker to identify polymor-
phisms can vary considerably and reflects an estimate 
of the multiplicity of infection. For this part of the study, 
many samples (22 out 51) that were selected have been 
previously characterized as multiple-clone infections [9, 
15, 35]. Thus, they were not used to determine the rate 
of multi-clonal infection and the genetic diversity of this 
parasite population in order to prevent overestimation. 
To compare the genetic diversity of parasite popula-
tions estimated by these markers, the available data for 
P. vivax from different geographic regions were com-
piled. The estimates of diversity were highest for the 
Fig. 1 Expected and normalized observed ratios of molecular marker alleles amplified from mixtures of cloned DNA with predominance of A-type 
allele (a) and B-type allele (b). Two microsatellite markers (PvMs6 and PvMS7), one tandem repeat (MN21), and three antigen-coding markers 
(msp1B2, msp1B10 and msp3α) were PCR amplified and analysed by capillary electrophoresis. The dotted line indicates the expected ratios of peak 
heights according to the proportion of molecules (cloned DNA) from each allele used as a template for PCR amplification. Data represent the aver-
age of two independent experiments
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antigen-encoding loci msp1B10 (HE range 0.880–0.902) 
and msp1B2 (0.813–0.875) (Additional file  6). For the 
microsatellites PvMS6, PvMS7, and MN21, only data 
from Brazil were available and the estimate of diver-
sity was lower (mean HE of 0.584, 0.785 and 0.650, 
respectively).
Discussion
Numerous studies have revealed substantial clonal 
diversity of Plasmodium within its vertebrate hosts. The 
characterization of this diversity can influence treat-
ment outcome and elucidate within-host dynamics that 
may be shaped by several factors, such as host immunity, 
density-dependent control mechanisms and drug treat-
ment [12, 21, 37]. Furthermore, estimates of within-host 
variability are relevant to correctly infer evolutionary 
and population genetics parameters, e.g., selection and 
recombination [18, 19]. To infer the multiplicity of infec-
tion of P. vivax, a panel of suitable molecular markers was 
Fig. 2 Detection of alleles in artificial mixtures of plasmid DNA by 
applying different criteria for rare allele identification. The frequency 
of detection of multiple alleles was calculated considering all 11 of 
the artificial mixtures assayed for each marker. The bars represent the 
total proportion of infections identified by each marker. Two criteria 
for minor allele detection were considered: a cut-off value of one-
third (colored in black only) or one-fourth (the entire bar, including 
both black and grey bars), of the height of the predominant peak. The 
increase in the rate of detection of alleles with one-fourth criterion is 
highlighted in grey
Fig. 3 Detection of multiple-clone infections in field samples. The six markers were genotyped in 51 samples from malaria-endemic area of Brazil. 
A cut-off value of one-fourth was considered for the analysis. a The frequency of multi-clonal infections was calculated considering both criteria for 
minor allele detection: a cut-off value of one-third (black bars only) or one-fourth (the entire bar, including both black and grey bars) of the height 
of the predominant peak. The increase in the rate of detection of multiple-clone infections with the one-fourth criterion is highlighted in grey. b 
Results of genotyping are shown for the 36 samples with multiple-clone infection detected by one (hatched rectangles) or more markers (rectangles 
colored in black). Each column represents the same sample genotyped with the six markers. The frequency of multi-clonal infections (% Total) was 
calculated for each marker. The increase in the number of multiple-clone infections detected, resulting from the combination of two or more mark-
ers, is indicated as the cumulative percentage (% Cum)
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defined herein, which included microsatellites, a tandem 
repeat and antigen-coding genes.
The analysis of artificial DNA mixtures with well-
defined proportions of cloned products showed that the 
commonly used msp1 antigen-coding marker and the 
tandem repeat MN21 allowed for the estimation of the 
expected ratio of both alleles in the majority of prepara-
tions when using normalized data. Conversely, the micro-
satellite markers were sensitive to the decreased relative 
abundance of alleles but, in addition to msp3α, did not 
accurately estimate the relative clonal proportions in arti-
ficial mixtures. For example, a preferential amplification 
of the shortest allele (with fewest repeats) for PvMS6 was 
consistently observed in tested dilutions. Accordingly, 
the preferential amplification of alleles of differing length 
was previously reported for other microsatellite and 
antigen-coding loci [38–40]. As indicated by Walsh et al. 
[32], the extent of preferential amplification is related 
to the size difference between the allelic PCR products, 
which was significantly greater for PvMS6 (102  bp). 
Although not assessed in this study, several other condi-
tions may lead to preferential PCR amplification, such as 
significant differences in the GC content between alleles, 
stochastic fluctuation in the presence of low amounts of 
target DNA molecules [39], and reduced amplification 
efficiency due to sequence polymorphism in the primer-
binding site [41]. Finally, the capillary-based instrument 
itself may introduce errors in measured relative density 
of the PCR product for each allele. However, instrument-
based errors are unlikely in this study because the results 
presented here indicate that the method is reproducible. 
Specifically, replicate experiments yielded similar results, 
as also reported in other studies [29].
Although some markers, such as the antigen-coding 
marker msp1 and the tandem repeat, provide an indica-
tion of the actual relative proportions of clones in artifi-
cial infections, the quantification yielded by the method 
described herein is subjected to limitations. First, tradi-
tional end-point PCR may lead to bias in the template-to-
product ratios of target sequences amplified during PCR, 
particularly for nested PCR, due to increasing numbers of 
PCR cycles [42, 43]. Thus, the amplification bias observed 
in the 1:1 mixtures and other dilutions of microsatellites 
and msp3α may be the result of reaction saturation (pla-
teau phase). At later cycles, the efficiency of PCR even-
tually declines for a number of reasons, including the 
exhaustion of reagents and the enzyme, the accumulation 
of inhibitors and the rehybridization of PCR products, 
which may interfere with primer binding or extension 
[43–45]. As a consequence, templates that reach inhibi-
tory concentrations essentially stop amplifying while 
others continue to efficiently undergo amplification. In 
addition, the results shown here and by others indicate 
that accurate quantification requires normalization using 
a baseline mixture of known proportion to calibrate 
samples to be analysed [24, 29, 30]. Such normalization 
restricts the use of this method for experimental infec-
tion models. To circumvent these limitations, quantita-
tive PCR (qPCR) or next-generation sequencing (NGS) 
may be applied to more reliably estimate the relative 
abundance of clones in an infection. Whereas qPCR is 
restricted to known single-species infections, like the 
method described here [40], the applications of NGS are 
much broader. As recently published for P. falciparum 
and P. vivax, NGS robustly represents clonal multiplicity 
and is very promising for drug-resistance or population 
genetics studies [46–49]. Nevertheless, genomic-level 
studies remain infeasible in many settings.
Many criteria have been used to differentiate rare 
alleles from artifacts, such as stutter (peaks that result 
from DNA strand slippage during PCR at intervals cor-
responding to nucleotide repeat sizes) or non-specific 
peaks [15, 16, 31]. Because the sensitivity and specific-
ity of these criteria can vary, comparing studies that 
applied different criteria is problematic. The present 
study sought to compare the rates at which multi-clonal 
infections were detected using the two criteria that are 
frequently applied to score multiple alleles per locus, i.e., 
minor peaks ≥33  % or ≥25  % of the height of the pre-
dominant peak. Overall, the one-fourth criterion allowed 
the detection of rare alleles in more unbalanced mixtures 
and the detection of significantly more alleles, especially 
for microsatellite markers. The results clearly show that 
when the one-third criterion is applied for microsatel-
lites, multi-clonal infections may be underestimated, 
even when the clones were present in similar propor-
tions. This finding was not surprising because several 
technical difficulties have been described related to the 
scoring of microsatellite alleles, such as the preferential 
amplification of alleles with fewer repeats and the higher 
probability of failing to detect the less abundant alleles 
[24, 30].
This study examined six loci were of differing molec-
ular features that have been widely used in studies of 
population genetics and the molecular epidemiology of 
vivax malaria [9, 12, 15, 35]. These loci included selec-
tively neutral and non-neutral markers on different 
chromosomes and markers differing in mutation rate 
(microsatellites, a tandem repeat and an antigen-encod-
ing gene). Thus, most of the variability of P. vivax popu-
lations should have been captured, and the within-host 
diversity should have been effectively characterized in 
different epidemiological settings. In these areas, several 
factors may modulate the genetic variability of a locus 
and/or of complete genomes, such as the malaria trans-
mission rates, selective constraints imposed by the host’s 
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immunity and anti-malarial drug use, and the historical-
demographic processes of the parasite population. Com-
piling the available data on the genetic diversity of P. 
vivax from different geographic regions higher estimates 
of diversity were found for antigen-encoding loci and 
less variable estimates for microsatellites and tandem 
repeat loci. When samples from the Brazilian Amazon 
were genotyped for all six markers, msp1B10, micros-
atellite markers and the tandem repeat MN21 yielded 
similar results. Interestingly, a significant difference was 
observed between blocks 2 and 10 of msp1. Whereas 
msp1B10 was able to detect almost 40 % of the 36 multi-
clonal infections identified, msp1B2 allowed the detec-
tion of only 6  % of these infections. Moreover, msp3α 
also showed poor performance in the detection of mul-
tiple-clone infections from field samples. Because these 
loci encode antigens exposed to the immune system, 
these results suggest that the patterns observed could 
reflect the different regimes of immune selection that 
these antigens are exposed to in this population. Nota-
bly, 50 % of the multiple-clone infections were detected 
by only one marker, indicating that adding additional 
loci may further increase the probability of detecting 
these infections.
Determining whether a sample is mono-clonal or con-
tains multiple clones of the parasite requires the careful 
selection of markers because most randomly selected 
markers may not faithfully depict the true complexity 
of an infection. Based on the performances of the six 
markers used here to characterize parasite diversity in 
both artificial mixtures of clones and in field samples, 
the combination, including PvMS6, PvMS7, MN21, and 
msp1B10 were selected for use in molecular epidemiol-
ogy studies. These markers comprise a panel containing 
highly informative loci that exhibit genetic variability 
in all examined P. vivax populations as well as loci that 
are less sensitive to PCR amplification biases and were 
able to better characterize the multiplicity of infection. 
In this study, a PCR-CE was proposed for allele scor-
ing, which has the advantage of allowing the accurate 
and fast genotyping of a large number of field samples 
at relatively low cost. Furthermore, a less stringent cri-
terion for rare allele identification significantly increases 
the sensitivity of this method. Thus, a minimum of one-
fourth should be used as a cut-off value for minor peak 
detection. Although the results described apply to a 
small subset of alleles and field samples likely contain 
several unknown alleles, they reveal information about 
amplification bias, which can be used to identify mark-
ers and conditions under which such biases are mini-
mized. Field samples from the Brazilian Amazon region, 
an area of low and unstable malaria transmission, were 
used to define the proposed panel. Nevertheless, further 
characterization is required, especially in regions of 
high endemicity, where this panel would also provide 
information about multi-clonal infections due to the 
high genetic variability of parasite population in such 
areas.
Conclusions
This study showed that the analysed molecular mark-
ers varied in their ability to detect and estimate the rela-
tive abundance of different clones in a P. vivax infection, 
which may bias the estimated of the genetic diversity of 
the parasite population. Using artificial mixtures of DNA 
and the genotyping of field isolates from Brazil, four 
markers (two microsatellites, one tandem repeat and 
one antigen-encoding gene) were selected based on their 
ability to characterize the within-host parasite diversity. 
Moreover, the use of a less stringent criterion is recom-
mended to increase the probability of detecting rare 
alleles.
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